Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2012 May;17(9-10):419-24. doi: 10.1016/j.drudis.2011.12.020. Epub 2011 Dec 29.

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Author information

1
Pfizer, Departments of Pharmacokinetics, Dynamics and Metabolism, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK.

Abstract

In an effort to uncover systematic learnings that can be applied to improve compound survival, an analysis was performed on data from Phase II decisions for 44 programs at Pfizer. It was found that not only were the majority of failures caused by lack of efficacy but also that, in a large number of cases (43%), it was not possible to conclude whether the mechanism had been tested adequately. A key finding was that an integrated understanding of the fundamental pharmacokinetic/pharmacodynamic principles of exposure at the site of action, target binding and expression of functional pharmacological activity (termed together as the 'three Pillars of survival') all determine the likelihood of candidate survival in Phase II trials and improve the chance of progression to Phase III.

PMID:
22227532
DOI:
10.1016/j.drudis.2011.12.020
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center